More Special Issues

About the Journal

Clinical Medicine Research

(ISSN Online: 2326-9057)

About the Special Issue

A Special Issue of Clinical Medicine Research (ISSN Online 2326-9057)

Deadline for manuscript submissions: Oct. 31, 2022

The term “drug-induced neurologic disorders” (DIND) refers to unintended or undesirable effects on the nervous system caused by drugs or associated with drug use. Adverse drug reactions (ADRs) may be due to drugs for neurologic or other diseases. The exact incidence of DIND is unknown. Reported adverse effects of drugs on the nervous system form only a small proportion of all neurological disorders but they are under-recognized and under-reported. Our special issue will focus on three of the most dangerous and feared DIND: neuroleptic malignant syndrome, malignant hyperthermia, serotonin syndrome.
Neuroleptic malignant syndrome is a clinical condition characterized by mental status changes, generalized rigidity, fever, and dysautonomia and it almost always occurs after “inappropriated response” to administering neuroleptic medication. Prevalence estimates range from 0.167 cases per thousand people to 32.6 cases per thousand people. A meta-analysis that analyzed the epidemiological data available in the literature yielded an overall estimate of 0.991 cases per thousand people. The pathogenesis and cause of neuroleptic malignant syndrome remain unclear. Malignant hyperthermia (MH) is an acute life-threatening hypermetabolic syndrome that occurs in susceptible individuals during exposure to inhalational anesthetic gases or the depolarizing neuromuscular blocker succinylcholine. The signs of MH can be variable and include respiratory acidosis, metabolic acidosis, generalized rigidity, rhabdomyolysis, and hyperthermia. The incidence of MH reactions ranges from 1:10,000 to 1: 250,000 anesthetics. However, the prevalence of the genetic abnormalities may be as great as one in 400 individuals. In fact, it occurs predominantly among people who have inherited a mutation of the skeletal muscle ryanodine receptor. Serotonin syndrome (SS), also referred to as serotonin toxicity, is a potentially life-threatening drug-induced toxidrome associated with increased serotonergic activity in both the peripheral (PNS) and central nervous systems (CNS). It is precipitated by the use of serotonergic drugs and overactivation of both the peripheral and central postsynaptic 5HT-1A and, most notably, 5HT-2A receptors. It includes neuromuscular abnormalities, autonomic hyperactivity, and mental state changes. Severe SS is only usually precipitated by the simultaneous initiation of 2 or more serotonergic drugs, but the syndrome can also occur after the initiation of a single serotonergic drug in a susceptible individual, the addition of a second or third agent to long-standing doses of a maintenance serotonergic drug, or after an overdose.
This special issue aims to help physicians working at emergency medicine departments to early suspect, recognize, diagnose and treat these potentially lethal syndromes, considering that the diagnosis is predominantly clinical. It will be focused on diagnosis (after exclusion of similar disorders) and treatment at the department of emergency. Case reports, case series, guidelines proposal will be accepted.

Keywords:

  1. Neuroleptic Malignant Syndrome
  2. Department of Emergency
  3. Malignant Hyperthermia
  4. Serotonine Syndrome
  5. Drugs and Neurological Disorders
  6. Evalutation, Diagnosis and Treatment
Lead Guest Editor
  • Filippo Manelli

    Director of Emergency Department Asst Bergamo Est (Seriate, Bergamo) , Seriate, Brescia, Italy

Guest Editor

A special issue is composed of a lead guest editor and a team of guest editors. Currently, there is no guest editor for this special issue and we sincerely invite the scholars in related fields to join it.

Join Us
Call for Papers

This special issue is open for submissions of original research. It accepts full papers, abstracts and tentative paper titles. The submission deadline is Oct. 31, 2022. Authors are encouraged to contribute research in related fields to the special issue.

Manuscript Submission

Publishing research works with Science Publishing Group is simple and efficient. Here are 3 ways for you to submit your manuscript.

1. Quick Submission

Quick Submission helps authors submit their manuscripts in a simple and quick way.

Special Issue Title*
Drug-induced Neurologic Disorders

Or click here to select another Special Issue that is more appropriate for your manuscript.

Select Another Special Issue
Step 1-Please Select a Category  *
  • Category
Step 2-Please Select a Special Issue  *
Special Issue Title
Article Processing Charge

1. Please select your research category in the left column first.
2. Then select a Special Issue to submit your paper in the right column.

Cancle Confirm
Type of Submission*

The submission can be in the forms of full paper, abstract or the tentative title of a paper.

Upload Full Paper*
Upload

1. Allow only .doc, .docx and .tex format.
2. Files should not exceed 20MB.

Paper Title*

Abstract*

Tentative Date for Submitting the Full Paper*

The submission deadline is Oct. 31, 2022.

Paper Title*

Tentative Date for Submitting the Full Paper*

The submission deadline is Oct. 31, 2022.

First Name*

Last Name*

Email Address*

A follow-up email will be sent to the given email address within 3 working days.

2. Email Submission

Manuscripts can also be submitted by the email. Please send your manuscript directly to this email address: submission_specialissue@sciencepg.com

Please type "Drug-induced Neurologic Disorders Manuscript Submission" as the subject of your email.

3. Online Submission

Authors can also log into the Online Submission System to finish the submission: https://sso.sciencepublishinggroup.com/login